Jul 2026· Cells and Development· Vol 187, pp.
204099
· 0 citations· 287 references
Medicine
TL;DR
Current mechanistic and clinical insights into the crosstalk between Wnt signaling and the RAS-RAF-MAPK and PI3K-AKT-mTOR pathways are synthesized, providing a conceptual framework for understanding signaling network crosstalk and identifying new therapeutic opportunities in cancer.
Abstract
The Wnt/β-catenin signaling pathway is a deeply conserved regulatory network that governs embryonic development, stem cell maintenance, and tissue homeostasis. Aberrant activation of the Wingless/Integrated protein (Wnt) signaling is a hallmark of numerous human diseases, most prominently in colorectal cancer, where it cooperates with additional oncogenic pathways to drive tumor initiation, progression, and therapeutic resistance (See Supplementary Table 1 for a list of the abbreviations used in this manuscript and their definitions.). Increasing evidence indicates that Wnt signaling does not function as an isolated linear cascade but rather as an integrative signaling hub that dynamically interfaces with major signaling pathways, including the RAS-RAF-MAPK and PI3K-AKT-mTOR pathways. Rat Sarcoma protein (RAS)- Rapidly Accelerated Fibrosarcoma protein (RAF)- Mitogen-Activated Protein Kinase (MAPK) and Phosphoinositide 3-Kinase (PI3K)- Ak strain transforming protein (AKT)- Mechanistic Target of Rapamycin (mTOR) pathways. These interactions occur at multiple molecular levels, encompassing shared kinases, transcriptional regulators, metabolic nodes, and cytoskeletal components, thereby coordinating proliferative, metabolic, and migratory programs. In this review, we synthesize current mechanistic and clinical insights into the crosstalk between Wnt signaling and the RAS-RAF-MAPK and PI3K-AKT-mTOR pathways, with particular emphasis on colorectal cancer. We discuss how these signaling networks converge to regulate β-catenin stability, transcriptional activity, cell adhesion, and metabolic reprogramming, thereby generating oncogenic phenotypes that cannot be explained by activation of individual pathways alone. To illustrate the evolutionary conservation and biological significance of these interactions, we integrate developmental paradigms from early Xenopus embryogenesis, where Wnt signaling governs zygotic genome activation, body axis formation, and the regulation of cell growth, protein stability, and biomass accumulation. Finally, we examine how an improved understanding of Wnt-centered signaling networks is informing emerging therapeutic strategies, including combinatorial pathway inhibition and nanoparticle-based drug delivery. Collectively, this review highlights Wnt signaling as a central integrator of developmental and oncogenic programs, providing a conceptual framework for understanding signaling network crosstalk and identifying new therapeutic opportunities in cancer.
The JAK/STAT signaling pathway regulates processes such as proliferation, differentiation, survival, and immune responses and is strongly correlated with the initiation and progression of several malignancies in humans.
Mariyam Rafi, U. Aiman, S. M. A. Shahid et al.· Current Cancer Therapy Revie...· 0 citations
This study comprehensively investigates PI3K/AKT signaling, elucidating its involvement across diverse human systemic tumors and analyzing the interplay between this pathway and other signaling cascades implicated in tumorigenesis.
Qingmiao Shi, Jie Liu, Qing-Fei Chu et al.· Signal Transduction and Targ...· 0 citations
Experimental results from breast, lung, gastric, liver, hematological, and melanoma models suggest that dysregulated PDK1 signaling can increase the output of the PI3K-AKT-mTOR pathway, invasion, metabolic adaptation, and resistance to specific hormonal, chemotherapeutic, and targeted therapies.
Darshana Ballagere Honnasiddappa, M. Ramar, Tincy Biju et al.· International Journal of Bio...· 0 citations
Phosphotyrosine-targeted mass spectrometry revealed robust phosphorylation of EPHA2 and EGFR upon Wnt inhibition, which suggests a Wnt-activated transcriptional repressor such as GATA3 that gates MAPK signaling in Wnt-high cancers.
Shawn R. Wadia, Chang-Yuan Hu, S. Patnaik et al.· JCI Insight· 0 citations
Key signaling pathways and emerging mechanisms in HCC and their roles in disease development and treatment are reviewed to lead to novel therapeutic targets and the development of more effective, personalized treatment strategies.
R. Srivastava, Pratibha Singh, D. Lonard· Biomedicines· 0 citations
Together, these studies emphasize that Wnt/ b -catenin signaling is controlled at multiple regulatory levels and cellular compartments, supporting context-speci c and biomarker-guided therapeutic strategies.
S. Patergnani, D. Buchsbaum, G. Piazza et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.